New combo therapy targets tough cancers

NCT ID NCT04421820

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers that have spread or cannot be removed. The goal is to see if the combination is safe and helps control tumor growth. About 220 adults will take part, first in a small dose-finding group, then in a larger group to measure how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AOU L. Vanvitelli

    NOT_YET_RECRUITING

    Naples, Italy

  • Azienda Ospedaliero Universitaria Pisana

    NOT_YET_RECRUITING

    Pisa, Italy

  • Cross Cancer Institue

    RECRUITING

    Edmonton, Alberta, Canada

  • Early Phase Unit FJD START Madrid

    NOT_YET_RECRUITING

    Madrid, Spain

  • Fondazione IRCCS "Istituto Nazionale dei Tumori

    NOT_YET_RECRUITING

    Milan, Italy

  • Hospital 12 de Octubre

    NOT_YET_RECRUITING

    Madrid, Spain

  • Jewish General Hospital

    RECRUITING

    Montreal, Quebec, Canada

  • Juravinski Cancer Centre

    RECRUITING

    Hamilton, Ontario, Canada

  • Kangbuk Samsung Hospital

    RECRUITING

    Seoul, South Korea

  • Mater Miserecordiae University Hospital

    RECRUITING

    Dublin, Ireland

  • McGill University Health Centre Glen Site

    RECRUITING

    Montreal, Quebec, Canada

  • Moffitt Cancer Center

    COMPLETED

    Tampa, Florida, 33612, United States

  • National Cancer Center

    RECRUITING

    Goyang, South Korea

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, Canada

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • Severance Hospital - Yonsei University

    RECRUITING

    Seoul, South Korea

  • St. James Hospital

    RECRUITING

    Dublin, Ireland

  • St. Vincent's University Hospital

    RECRUITING

    Dublin, Ireland

  • The Ottawa Hospital Cancer Centre

    RECRUITING

    Ottawa, Ontario, Canada

  • Universitatsklinikum Bonn

    RECRUITING

    Bonn, Germany

  • University Hospital of Ulm

    RECRUITING

    Ulm, Germany

  • University of California, Los Angeles

    COMPLETED

    Santa Monica, California, 90095, United States

  • Vall Hebron Institute of Oncology (VHIO)

    NOT_YET_RECRUITING

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.